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Summary  The  aim  of  the  present  study  was  to  increase  awareness  regarding
the  rational  use  of  medicines.  The  data  were  obtained  via  the  Material  Resources
Management  System  Module  of  the  Ministry  of  Health.  For  the  appropriatenessRational  use  of  drugs; of  treatments,  the  Global  Initiative  for  Asthma,  the  Global  Initiative  for  Chronic
Obstructive  Lung  Disease,  and  the  guidelines  for  the  rational  use  of  medicines  werePneumonia
used.  We  also  investigated  whether  any  de-escalation  method  or  physical  exercise
was  performed.  Statistical  analyses  were  performed  using  descriptive  statistics  to
determine  the  mean,  standard  deviation,  and  frequency.  The  results  showed  that
healthcare  providers  ignored  potential  drug  reactions  or  adverse  interactions,  and
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he  World  Health  Organization  (WHO)  reported  that
hronic respiratory  system  diseases  will  increase
n the  future  as  a  result  of  air  pollution,  global
arming, and  smoking  [1].  In  addition,  chronic
bstructive pulmonary  disease  (COPD)  and  pneu-
onia have  been  predicted  as  two  of  the  leading
auses of  death  [1,2].  In  addition,  the  cost  of  the
rugs and  pharmaceutical  products  (DPP)  used  for
he treatment  of  these  diseases  has  been  huge  bur-
en on  government  economies  and  social  security
dministrations [3,4]. Studies  have  also  reported
hat chronic  diseases  pose  a  threat  to  public  health,
nd it  might  not  always  be  possible  to  access  effec-
ive treatments  due  to  cost-related  factors  [5].
The aim  of  all  healthcare  providers  is  to  effec-
ively treat  patients  and  avoid  adverse  reactions  to
edicine [6].  The  aim  of  the  present  study  was  to
educe the  economic  cost  of  medical  treatments
ia the  implementation  of  policies  regarding  the
ational  use  of  drug.  Despite  the  massive  efforts
f infection  control  committees,  antibiotics  have
een irrationally  consumed  [7,8].
The present  study  included  patients  with  COPD
r pneumonia,  diagnosed  and  admitted  with  chest
iseases  at  a  state  hospital.  The  aim  of  the
resent study  was  to  investigate  the  compliance  of
ntibiotic  use  with  laboratory,  clinical,  and  recent
uidelines  and  increase  awareness  regarding  the
ational  use  of  drugs  via  the  estimation  of  unit
osts using  pharmacoeconomic  models,  including
ost-beneﬁt-analysis  (CBA)  and  cost-minimization
nalysis (CMA).
aterials and methods
nclusion criteria
he  study  population  included  1101  patients  admit-
ed to  the  Chest  Diseases  Service  (30  beds)  of
ekirdag˘ State  Hospital  (400  beds)  between  January
1, 2012  and  December  31,  2012.  For  cost  analyses,
ome patients  were  excluded  for  speciﬁc  reasons.
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ce  to  the  current  treatment  guides,  35.8%  irrational  use
hus,  de-escalation  methods  should  be  used  to  decrease
 spectrum,  antibiotic  selection  should  consider  the  resis-
thods  should  be  analyzed,  and  monotherapy  should  be
treatments.
ziz  University  for  Health  Sciences.  Published  by  Elsevier
According  to  the  diagnosis,  COPD,  pneumonia,
nd asthma  patients  were  included  in  the  present
tudy.  Apart  from  this,  intensive  care  unit  patients,
uberculosis,  bronchiectasis,  pulmonary  embolism,
iffuse  parenchymal  lung  disease  and  asthma,
neumonia with  diabetes  mellitus,  congestive  heart
ailure, chronic  renal  failure,  sinusitis,  and  aller-
ic rhinitis  were  excluded  from  the  present  study.
sthma and  COPD,  accompanied  by  pneumonia,
ere included  in  the  group  of  pneumonia  patients
Fig.  1).
The remaining  cases  (n  =  729)  were  included  in
he study.
ata collection
he  data  were  obtained  from  Material  Resources
anagement System  of  the  Ministry  of  Health.
he system  provided  diagnosis,  medical  history,
emographic  features,  and  treatment  data.  As  part
f the  treatment  info,  all  DPP,  including  feed-
ng solutions  and  serums  with  dose  information,
nd culture  antibiogram  results  for  patients  who
sed antibiotics  were  obtained  and  analyzed.  Drug
nteractions  commonly  encountered  in  the  patient
ecords  and  the  compatibility  of  these  substances
ith the  treatment  guides  and  guidelines  for  the
ational use  of  drugs  were  analyzed  [9,10]. More-
ver, whether  physical  exercise  was  recommended
o reduce  medicine  costs  was  examined  using  ran-
om sampling  in  10%  of  the  population.
ost evaluation
he  cost  of  the  drugs  and  pharmaceutical  products
as calculated  using  unit  prices  and  the  actual
mount of  medicine  used.  The  unit  prices  were
etermined using  the  price  list  published  by the
inistry  of  Finance  and  the  Turkish  Pharmaceutical
nd Medical  Device  Agency  [11].  Following  the
alculation  of  the  cost  of  antibiotics,  another  phar-
acoeconomic  analysis  was  performed  using  the
MA method,  involving  an  alternative  treatment
ethod comparable  but  more  economical  than
44  M.  Dogan  et  al.
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that  previously  administered  [12].  For  the  costs
calculated  in  Turkish  Liras  (TL),  the  Euro  (D  ) equiv-
alent of  TL  of  the  period  of  expenditure  was  used
for standardization  (1  D  =  1.9595  Turkish  Liras).
Statistical evaluation
Descriptive  analyses  (mean,  standard  deviation,
frequency) of  the  data  obtained  through  a  routine
data recording  system  were  made.  To  calculate  the
total pharmaceutical  cost,  the  daily  consumption
of medicine  was  obtained  after  multiplying  the  box
or unit  price  by  the  number  of  boxes  or  units.  To
calculate the  mean  total  cost,  the  total  cost  was
divided  by  the  number  of  patients.  The  daily  cost
per patient  was  calculated  by  dividing  the  mean
total cost  by  the  mean  hospital  stay  (days).
Ethics committee approval
The  approval  of  the  Tekirdag  Province  General  Sec-
retariat  of  State  Hospitals  Association  was  obtained
on May  15,  2013,  and  the  study  was  approved
through the  Local  Ethics  Committee  of  Namik  Kemal
University  Faculty  of  Medicine  on  June  27,  2014,
approval number  2013.70.06.01/01.
Results
The  study  included  729  patients  (67.7%  male;  32.3%
female)  diagnosed  with  asthma,  COPD,  or pneu-
monia. The  mean  ages  of  the  male  and  female
patients were  70.38  ±  0.50  and  69.09  ±  15.62  years
old, respectively.  The  mean  hospital  stay  of  the
m
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S exclusion  criteria.
atients  was  21  days.  The  longest  hospital  stays
ere 41  days  for  COPD  patients,  8  days  for  asthma
atients,  and  14  days  for  pneumonia  patients.  The
otal cost  of  inpatient  DPP  expenses  of  the  hospital
or the  year  in  which  the  present  study  was  con-
ucted was  D  2,017,307.03.  The  total  DPP  cost  of
he participants  of  the  present  study  for  the  same
ear was  D  373,497.45  (Table  1).
The  mean  total  cost  per  patient  was  D  512.34,
nd the  mean  daily  cost  per  patient  was  D  24.40.
he mean  total  cost  of  antibiotic  use  was  D  350.80.
he  total  DPP  cost  of  the  excluded  patients  was
 234,187.70/year.  The  most  popular  antibiotics
ospital-wide during  the  study  period  was  cef-
riaxone  with  43,405  units  costing  a total  of
 220,846.06;  however,  among  the  study  group,
oxiﬂoxacin was  the  most  popular  antibiotics  with
676 units  consumed  costing  D  104,154.90  (Fig.  2).
Quinolones were  used  the  most  in  both  study
roups and  throughout  the  entire  hospital.  The  total
ost of  the  antibiotic  use  of  the  study  group  was
9.05% of  the  total  cost  of  antibiotic  use  at  the
ospital for  the  same  time  period  (Fig.  3).
A total  of  929  samples  were  collected  from
he study  group:  529  sputum  samples,  197  urine
amples,  180  blood  samples,  and  23  endotracheal
spirate culture-antibiogram  samples  (Fig.  4).
Approximately 52.81%  of  the  patients  whose  cul-
ures showed  no  signiﬁcant  growth  were  prescribed
 combination  of  moxiﬂoxacin  (400  mg/day)  and
eftriaxone  (2  g/day)  for  8  days.  In  addition  to
oxiﬂoxacin  and  ceftriaxone,  ampicillin  sul-
actam  (2  g/day)  was  administered  to  7.13%  of
he participants  (n  =  52)  for  10  days.  Patients  with
treptococcus  (n =  1)  were  treated  with  ceftriaxone
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Table  1  The  total  DPP  costs  of  the  entire  hospital,  and  patients  with  asthma,  COPD,  or  pneumonia  for  the  study
period.
Pharmaceutical  product  Study  group
cost  (D  )/year
Hospital  cost
(D  )/year
Study  group
%  (D  )
Study  group
(%)
Antibiotics  255,730.99  1,342,784.18  19.05  13.55
Inhaled  bronchodilators  and  steroids 54,837.64 170,749.17 32.12  24.52
Montelukast  142.98 436.74 32.73 32.74
Acetylcysteine  5723.49 32,488.51 17.62 22.77
Corticosteroids  oral  and  IV  13,339.07  105,714.39  12.62  10.49
LMWHa 22,411.46  186,677.93  12.01  12.11
H2 R.A.b 14,477.33  98,752.18  14.66  11.31
Allopurinol  21.61  89.67  24.11  11.44
PEFPc 6812.88  79,614.26  8.56  10.53
Total  373,497.45  2,017,307.03  18.52  16.98
a LMWH: low molecule weighted heparins.
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c PEFP: parenteral and enteral feeding products.
2  g/day)  and  moxiﬂoxacin  (400  mg/day),  although
his pathogen  is  susceptible  to  penicillin,  and
o penicillin  allergies  were  reported.  In  a  COPD
atient affected  with  the  Enterobacteriaceae,
lthough  the  culture  antibiogram  result  showed
usceptibility to  amikacin,  ciproﬂoxacin,  and
evoﬂoxacin,  the  patient  was  empirically  treated
ith  ceftriaxone  and  moxiﬂoxacin.
Approximately  11.65%  of  the  patients  (n  =  85),
ith CRP  and  WBC  values  within  the  normal
ange and  antibiogram  results  showing  no  signiﬁ-
ant growth,  were  treated  with  both  ceftriaxone
w
m
(
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Figure  2  Antibiotics  administ2  g/day)  and  moxiﬂoxacin  (400  mg/day).  Notably,
5% of  the  pathogenic  bacteria  in  the  culture  mate-
ials (n  = 8)  were  susceptible  to  levoﬂoxacin;  thus,
oxiﬂoxacin  was  prescribed  costing  D  114.20  per
atient.
Carbapenem  and  quinolone  antibacterials  were
rescribed  (n  =  10),  although  the  antibiogram
esults showed  no  need  for  antibacterials,
hich cost  the  hospital  D  1431.90.  Due  to
ethicillin-resistant  Staphylococcus  aureus
MRSA), this  patient  was  switched  to  linezolid  and
ephoperazone-sulbactam.  Similarly,  empirically
ered  to  the  study  group.
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eFigure  3  Comparison  of  the  amount  of  antibiotics  cons
(D  ).
treatments  with  ceftriaxone  and  moxiﬂoxacin
were switched  to  carbapenem  and  teicoplanin,
although no  culture  growth  was  observed  (n  = 6).  In
261 of  the  729  patients  (35.80%),  based  on  culture
antibiogram results  and  treatment  guides,  the
irrational  use  of  medicines  was  observed.
In patients  diagnosed  with  asthma  (n  = 112),
treatments not  compatible  with  the  Global
a
s
(
Figure  4  Results  of  the  culture  antibiogram  obtaine by  the  study  group  and  throughout  the  entire  hospital
nitiative  for  Asthma  (GINA)  guide  were  observed
9]  (Table  2).
According  to  the  GINA  guidelines,  antibiotics
re not  routinely  recommended  in  asthma  exac-
rbations.  However  for  asthma  occurrences  not
ccompanied  by  infections,  such  as  pneumonia  and
inusitis, the  patients  were  treated  with  antibiotics
n =  112).
d  from  the  patients  in  the  study  group  (n  =  929).
Rational  drug  use  policies  in  the  respiratory  system  dise
Table  2  Medication  not  suitable  for  asthma
treatment.
Pharmaceutical  product  Numeral  Cost  (D  )
Ampicillin  sulbactam  249  359.62
Cefazolin  46  117.38
Cefuroxime  680  30,711.9
Ceftrixone  491  2498.22
Ciproﬂoxacin  44  604.26
Levoﬂoxacin  59  122.55
Moksiﬂoxacin  tablet  198  448.65
Moksiﬂoxacin  vial  229  6488.43
Cefoperazone  sulbactam  6  38.64
Piperacillin  sulbactam  93  1100.15
Meropenem  11  132.03
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rLinezolid  18  1120.24
LMWH  194  926.69
Notably,  3770  units  of  acetylcysteine  were
sed in  various  treatments  for  patients  with
ronchospasm (n  =  197).  Theophylline  and  other
ethylxanthines  were  used  with  allopurinol  (n  = 6)
nd/or ﬂuoroquinolones  (n  = 44).  In  patients  with
espiratory  tract  infections  (n  =  5),  montelukast  was
sed. Pulmonary  rehabilitation  was  not  recom-
ended to  any  of  the  patients.
iscussion
he  estimation  of  unit  drug  costs,  among  the  direct
osts in  healthcare  services,  is  crucial.  For  hos-
itals, the  treatment  cost  of  respiratory  system
iseases, such  as  asthma,  COPD,  and  pneumonia,
re a  large  portion  of  the  total  hospital  expenses
13].  The  cost  of  treatments  for  respiratory  diseases
omprised  6%  of  the  allocated  total  healthcare-
elated budget  in  EU.  Majority  of  this  cost  (56%,
8.6 billion  D  )  was  COPD-related  [14,15]. The
irect cost  of  COPD  in  the  US  was  estimated  as  29.5
illion  USD,  with  an  additional  estimated  indirect
ost of  20.4  billion  USD  [16]. Although,  previous
tudies have  investigated  strategies  to  achieve  the
ost effective  treatment  of  asthma  [17],  there  are
ew pharmacoeconomic  studies  investigating  the
ost of  drugs  [18].
The  aims  of the  present  study  aims  was  to  inves-
igate the  cost  of  DPP  for  the  treatment  of  patients
dmitted  with  asthma,  COPD,  and  pneumonia  and
ssess the  compatibility  of  DPP  use  of  the  cohort
ith the  current  treatment  guidelines.
In the  literature,  it  has  been  reported  that
he mean  hospital  stay  and  cost  per  person  for
neumonia patients  were  4  days  and  256.63  USD,
espectively,  and  the  Global  Initiative  for  Chronic
bstructive  Lung  Disease  (GOLD)  2014  Guide  rec-
mmends  5—10  days  of  antibiotic  treatment  for
t
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hese  patients  [10,19,20]. In  addition,  antibiotic
se in  patients  with  COPD  exacerbations  might  sig-
iﬁcantly reduce  the  duration  of  the  hospital  stay
21].
In the  present  study,  the  cost  of  antibiotics  in
atients with  asthma,  COPD,  and  pneumonia  was
9.05% of  the  total  cost  of  antibiotics  used  at  the
ospital during  the  same  time  period,  and  the  cost
f DPP  and  antibiotics  per  person  was  D  512.34  and
 350.80,  respectively.  The  mean  hospital  stay  was
1 days,  and  all  patients  were  administered  antibi-
tics. Compared  with  previous  studies,  the  mean
ost per  person  was  higher  in  the  present  study,
ssociated with  a longer  hospital  stay.
Boucher  et  al.  investigated  the  cost  of  DPP,
ccurrence of  hospital  infections,  use  of  drug
roups, and  duration  of  hospital  stay  in  278  inpa-
ients. These  authors  reported  that  DPP  use  for
ntimicrobial  treatment,  stress  ulcer  prophylaxis,
nd bronchodilator  treatment  comprised  more  than
6% of  the  total  DPP  use  [22].
In the  present  study,  the  use  of  the  same  DPP  was
9.92% of  the  total  DPP  use  of  the  entire  hospital
nd 87.03%  for  the  study  group,  and  these  results
ere  higher  than  the  ﬁndings  of  Boucher  et  al.  This
ifference  might  reﬂect  the  fact  that  the  present
tudy  included  patients  with  respiratory  diseases,
hus bronchodilator  use  was  substantial.  However,
he difference  between  hospital-wide  values  might
arrant  an  investigation  of  the  drug  use  indications.
Previous studies  have  shown  that  the  difﬁculty
n differentiating  infectious  and  non-infectious
athologies  in  pneumonia  diagnosis  might  result  in
he irrational  use  of  antibiotics,  thereby  leading
o infections  with  bacteria  resistant  to  antibiotic
oxicity and  an  increase  in  the  cost  of  treat-
ent [23,24]. In  COPD  exacerbations,  50—70%
f tracheobronchial  infections  (bacterial  factors
0—50%, viral  factors  30—40%,  atypical  bacte-
ial factors  5—10%)  and  10%  of  the  air  pollution
ere cited  among  the  causes,  but  in  30%  of  the
ases, no  etiology  was  reported  [25]. In  addition
o the  difﬁculty  in  obtaining  a differential  diag-
osis,  amoxicillin,  beta-lactam  and  beta-lactam
nhibitors, second-generation  cephalosporins,  and
acrolides were  administered  for  mild  exacerba-
ions of  COPD;  third-generation  cephalosporins  or
espiratory ﬂuoroquinolones  were  administered  for
oderate exacerbations  of  COPD;  and  antipseu-
omonal antibiotics  were  administered  for  acute
xacerbations  of  COPD  and  exacerbations  with  a
isk of  Pseudomonas,  according  to  the  Jindal  for
he COPD  Guidelines  Working  Group  [26].
The GOLD  recommends  clavulanic  acid
nd/oraminopenicillin  or  tetracycline  for  the  initial
reatment  of  pneumonia.  For  hospitalized  patients
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in  general  wards,  the  IDSA/ATS  guidelines  recom-
mend antipneumococcal  ﬂuoroquinolone  (e.g.,
levoﬂoxacin,  moxiﬂoxacin)  or  the  combination
beta lactam  plus  macrolide  [10,27].
Moreover,  routine  antibiotics  therapy  for  asthma
exacerbations  is  not  recommended  [12,15,28,29].
All patients  participating  in  the  present  study
were administered  antibiotics,  and  the  choice  of
antibiotics  was  primarily  a  combination  of  ceftri-
axone  and  moxiﬂoxacin,  instead  of  monotherapy.
Notably, the  use  of  the  combination  of  ceftriaxone
and moxiﬂoxacin  instead  of  monotherapy  resulted
in overspending,  totaling  D  36,801.74.  In  addi-
tion, the  use  of  moxiﬂoxacin  ﬂacon  (D  104,154.90,
3676 units/year)  instead  of  levoﬂoxacin  ﬂacon
resulted in  overspending,  totaling  D  51,683.49.  Fur-
ther, despite  the  lack  of  any  evidence  of  infection
accompanying  asthma,  antibiotics  in  the  amount  of
D 43,742.07  were  used.
A current  treatment  guide  states  that  imipenem,
meropenem, ertapenem,  colymicin,  vancomycin,
teicoplanin, linezolid,  and  tigecycline  should
not be  part  of  an  empirical  treatment,  and
antipseudomonal  antibacterials,  such  as,  cef-
tazidime,  cefepime,  cephoperazone  sulbactam  and
piperacillin tazobactam,  should  be  administered
only in  a  risky  group  [19].
The eligibility  of  the  antibiotics  was  evaluated
according to  antibiotic  culture  test  results.  Radio-
logical,  sputum,  white  blood  cell  count,  fever,  and
C-reactive  protein  were  also  evaluated.  In  patients
without  infectious  diseases,  empirical  treatment
and antibiotics  overuse  were  evaluated.
In  the  present  study,  however,  there  were
indications of  the  use  of  these  antibiotics  in
only ﬁve  patients,  and  these  drugs  were  irra-
tionally used  for  other  patients,  resulting  in
overspending, totaling  D  71,947.75.  In  addition,
MRSA patients  were  switched  to  linezolid  and
cephoperazone-sulbactam  instead  of  treatment
with linezolid.  However,  the  reason  for  the  addi-
tion of  cephoperazone-sulbactam  treatment  was
not understood.
A total  of  52.81%  of  the  patients  with  cultures
showing no  signiﬁcant  growth  were  adminis-
tered moxiﬂoxacin  (400  mg/day)  and  ceftriax-
one (2  g/day)  for  8  days,  costing  the  hospital
D 87,267.97  and  D  29,714.11,  respectively.  Addi-
tionally,  in  7.13%  of  the  patients,  ampicillin
sulbactam  (2  g/day)  was  administered  in  addi-
tion to  moxiﬂoxacin  (400  mg/day)  and  ceftriax-
one (2  g/day),  resulting  in  overspending,  totaling
D 1502.02.  In  patients  with  cultures  showing  strep-
tococcus,  instead  of  penicillin  costing  only  D  39.20,
ceftriaxone  and  moxiﬂoxacin  were  administered,
which cost  the  hospital  D  283.34.
a
b
b
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Although  the  rate  of  identifying  the  active
athogen via  culture  growth  in  Turkey  is between
1% and  44%,  this  rate  was  1.7%  in  the  present
tudy. A  study  on  culturing  and  increasing  the  rate
f identifying  the  active  pathogen  would  increase
he effectiveness  of  such  probes  and  facilitate  the
election  of  the  appropriate  antibiotics  and  thereby
educe hospital  costs.  Considering  the  antibiogram
esults and  the  resistance  patterns  in  261  of  the  729
atients (35.80%),  the  irrational  use  of  antibiotics
as clearly  observed.
Previous  studies  have  reported  that  the  current
nd effective  treatment  might  not  always  be  acces-
ible under  ﬁnancial  restrictions,  and  thus,  similar
PP with  a lower  cost  might  be  selected  [12,30,31].
owever, maintaining  the  empiric  antibiotic  regi-
en until  the  end  of  the  treatment  has  also  been
eported  [30].
Low-molecular-weight  heparins  (LMWHs)  are
sed in  the  treatment  of  venous  thromboembolism,
hich frequently  occurs  among  patients  and  is  an
voidable cause  of  death  [31—38]. For  immobile,
olysemic, and  dehydrated  COPD  patients,  prophy-
axis is  recommended.  Moreover,  in this  guideline,
he use  of  LMWH  for  infectious  asthma  exacerba-
ions was  considered  appropriate  [10,33].  Studies
ave shown  that  for  each  attempt  to  avoid  deep
ein thromboembolism,  the  use  of  LMWH  resulted  in
391 savings  based  on  a pharmacoeconomic  model,
lthough  the  use  of this  drug  was  a  large  portion  of
he total  DPP  budget  of  the  hospital  [34,36].
In the  present  study,  in  COPD  and  pneumonia
atients and  asthma  patients  experiencing  exac-
rbation,  prophylactic  LMWH  was  used,  consistent
ith the  literature.  However,  LMWH  was  adminis-
ered  to  patients  with  no  indication  of  infection,
hich increased  the  costs.
Although  a systemic  review  claimed  that  in  COPD
atients,  mucoactive  agents  reduce  the  frequency
f exacerbations  and  decrease  COPD-related  dis-
bilities,  recent  studies  have  shown  that  these
ffects and  the  positive  effects  on  the  quality  of
ife are  minimal  [10,39]. Therefore,  the  routine
dministration  of  these  drugs  in  COPD  treatment
s not  recommended,  but  patients  who  experience
enacious sputum  might  beneﬁt  from  mucolytics
10,38].  In  addition,  some  studies  have  reported
p to  48%  severe  bronchospasm  resulting  from
cetylcysteine [39,40]. In  the  present  study,  acetyl-
ysteine  was  administered  to  patients,  resulting
verspending, totaling  D  14,630.98.
In the  present  study,  theophylline,  which  has weaker  bronchodilator  efﬁcacy  compared  with
eta-agonist  agents,  might  have  been  administered
ecause this  antibiotic  does  not  cause  tolerance
n patients  with  bronchial  asthma  after  long-term
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se.  However,  when  administering  theophylline,
ealthcare providers  did  not  consider  that  theo-
hylline interacts  with  several  agents,  and  the
ffectiveness  is  reduced  or  toxicity  is  increased
hen used  with  several  agents,  such  as  antiarrhyth-
ics, allopurinol,  ciproﬂoxacin,  and  levoﬂoxacin
ecause the  theophylline  biotransformation  is  sup-
ressed. Theophylline  or  other  methylxanthines
ere administered  to  six  patients  using  allopurinol
nd 44  patients  using  ﬂuoroquinolones  through-
ut the  hospital  stay  without  considering  any  drug
nteraction.
Montelukast,  a  leukotriene  receptor  antagonist,
hich can  be  used  in  addition  to  glucocorticoid
nd beta  agonists  in  patients  with  mild  and  mod-
rate asthma  and  in  patients  with  asthma  induced
hrough  exercise,  cannot  be  used  alone  in  chronic
sthma treatment  because  this  drug  increases  the
isk of  respiratory  tract  infection  [40].  The  GINA
uide recommends  montelukast  in  asthma  treat-
ent for  stage  2  patients  as  an  alternative  to
nhaled steroids  [9]. For  stage  3  and  above  asthma
atients, inhaled  steroids  are  recommended.  How-
ver, antibiotic  treatment  is  not  recommended  for
sthma patients  without  pneumonia  and  sinusitis
9].
In the  present  study,  montelukast  was  adminis-
ered to  ﬁve  patients,  which  was  not  part  of  the
reatment or  prophylaxis  of  COPD.  This  irrational
se of  montelukast  caused  the  overspending  of  hos-
ital funds  on  DPP.
Pulmonary  rehabilitation  is  an  indirect  factor
ecreasing the  symptoms  in  COPD  patients,  increas-
ng the  quality  of  life,  and  enhancing  the  efﬁcacy
f the  treatment,  thereby  decreasing  the  cost.
siachristas  et  al.  investigated  the  changes  in
ost-effectiveness  in  1322  patients  treated  in  16
ifferent  disease  management  plans.  These  authors
bserved  that  physical  activity  (21%)  in  COPD
atients had  a  signiﬁcant  positive  effect  on  cost-
ffectiveness  [41].
Among  the  randomly  selected  data  (10%),
o pulmonary  rehabilitation  recommendation  was
bserved;  therefore,  the  cost-effectiveness  anal-
sis of  the  pulmonary  rehabilitation  and  the
ost-utility analysis  of  the  increased  quality  of  life
ere not  conducted,  which  could  be  considered  as
 limitation  of  the  present  study.
The total  DPP  cost  of  the  inpatients  in  the  study
eriod was  D  2,017,307.03,  with  D  373,497.45  for
sthma,  COPD,  and  pneumonia  patients  for  the
ame time  period.  The  average  total  DPP  cost  per
atient  was  D  512.34,  the  average  daily  cost  per
atient  was  D  24.40,  and  the  average  total  cost  of
ntibiotic  therapy  per  person  was  D  350.80.  Mox-
ﬂoxacin  was  the  most  popular  antibiotic  with  a
T
r
o
tases  49
otal  annual  cost  of  D  104,154.90.  All  patients  in  the
tudy group  were  initially  administered  antibiotics,
nd the  choice  of  antibiotic  treatment  was  primar-
ly a combination  of  ceftriaxone  and  moxiﬂoxacin
nstead of  monotherapy,  which  cost  the  hospital
 36,801.74,  and  the  use  of  levoﬂoxacin  instead  of
oxiﬂoxacin  cost  the  hospital  D  52,471.41.  It  was
 frequent  practice  to  initiate  empirical  antibiotic
reatment  and  complete  the  treatment  using  the
ame regimen;  moreover,  no  de-escalation  practice
as observed  to  decrease  the  cost  and  narrow  the
ntibiotic  spectrum.  Considering  the  results  of  the
ulture antibiograms  and  treatment  guide  recom-
endations,  the  irrational  use  of  antibiotics  was
bserved.  Moreover,  interactions  among  drugs  were
isregarded,  and  several  occasions  of  drug  use  con-
radicting  the  treatment  guides  were  observed.  No
ulmonary  rehabilitation  was  recommended  to  the
atients.
onclusion
ased  on  the  culture  antibiogram  results  and
elated resistance  patterns,  the  irrational  use  of
ntibiotics  should  be  avoided.  To  this  end,  cul-
uring methods  should  be  re-evaluated,  and  the
uccessful  identiﬁcation  of  active  pathogens  should
ncrease the  effectiveness  of  culturing  and  facil-
tate the  selection  of  the  appropriate  antibiotic
herapy, which  would  eventually  decrease  the  DPP
osts. Patient  care  should  be  approached  from  a
ulti-disciplinary  point  of  view  and  evidence-based
uidelines should  be  used.  Teams  should  be  estab-
ished and  led  by  experts  of  infectious  diseases
nd pharmacology.  In hospitals,  pharmacoeconomic
odels and  health  economy  policies  should  be
rgently  implemented.
unding
o  funding  sources.
ompeting interests
one  declared.
thical approvalhe  approval  of  the  Tekirdag  Province  General  Sec-
etariat of  State  Hospitals  Association  was  obtained
n May  15,  2013,  and  the  study  was  approved
hrough the  Local  Ethics  Committee  of  Namik  Kemal
[[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[50  
University  Faculty  of  Medicine  on  June  27,  2014,
approval number  2013.70.06.01/01.
References
[1] WHO. Global surveillance, prevention and control of
Chronic Respiratory Diseases. A comprehensive approach.
Geneva: WHO; 2007. http://www.who.int/respiratory/
publications/global surveillance/en/ [accessed 14.09.14].
[2] Wunderink RG, Waterer GW. Clinical practice. Community-
acquired pneumonia. N Engl J Med 2014;370:543—51.
[3] Hoogendoorn M, Feenstra TL, Asukai Y, Borg S, Hansen
RN, Jansson SA, et al. Cost-effectiveness models for
chronic obstructive pulmonary disease: cross-model com-
parison of hypothetical treatment scenarios. Value Health
2014;17:525—36.
[4] Lenferink A, Frith P, van der Valk P, Buckman J, Sladek R,
Cafarella P, et al. A self-management approach using self-
initiate d’action plans for symptoms with on going nurse
support in patients with Chronic Obstructive Pulmonary Dis-
ease (COPD) and comorbidities: the COPE-III study protocol.
Contemp Clin Trials 2013;36:81—9.
[5] Nolte E, Mckee M. Caring for people with chronic conditions.
In: Nolte E, Mckee M, editors. Making it happen. 2nd ed.
Berkshire, England: Open University Press; 2008. p. 161.
[6] Wettengel R. Long term treatment of COPD with
theophylline still a valuable option. Pneumologie
2003;57:598—605.
[7] Malo S, Bjerrum L, Feja C, Lallana MJ, Poncel A,
Rabanaque MJ. Antibiotic prescribing in acute respira-
tory tract infections in general practice. An Pediatr (Barc)
2014;(14):1695—4033.
[8] Joergensen JS, Weile LK, Lamont RF. The early use of appro-
priate prophylactic antibiotics in susceptible women for the
prevention of preterm birth of infectious etiology. Expert
Opin Pharmacother 2014;15:2173—91.
[9] GINA Report. Global Strategy for asthma management;
2014. http://www.ginasthma.org/documents/4 [accessed
07.10.14].
[10] Global Initiative for Chronic Obstructive Lung Disease.
NHLBI/WHO Global Initiative for Chronic Obstructive
Lung Disease Workshop report. Global strategy for the
diagnosis, management and prevention of chronic obstruc-
tive pulmonary disease; 2014. http://www.goldcopd.com/
[accessed 17.09.14].
[11] Drug price list, 2012. http://www.iegm.gov.tr [accessed
09.08.14].
[12] Smith MC, Wertheimer AI. Predicting and detecting non
compliance. In: Smith MC, editor. Social and behavioral
aspects of pharmaceutical care. 13th ed. New York: Phar-
maceutical Products Press; 1996. p. 165—9.
[13] Patankar AM, Trivedi PL. Monetary burden of health impacts
of air pollution in Mumbai, India: implications for public
health policy. Public Health 2011;125:157—64.
[14] Chapman KR, Mannino DM, Soriano JB, Vermeire PA,
Buist AS, Thun MJ, et al. Epidemiology and costs of
chronic obstructive pulmonary disease. Eur Respir J
2006;27:188—207.
[15] Bentley CL, Mountain GA, Thompson J, et al. A pilot ran-
domised controlled trial of a Telehealth intervention in
patients with chronic obstructive pulmonary disease: chal-
lenges of clinician-led data collection. Trials 2014;15:313.
[16] National Heart, Lung and Blood Institute. Morbidity and
Mortality chart book on cardio vascular, lung and blood dis-
eases. Bethesda, Maryland: US Department of Health and
[
[M.  Dogan  et  al.
Human Services, Public Health Service, National Institutes
of Health; 2012.
17] Price D, Small I, Haughney J, Ryan D, Gruffydd-Jones
K, Lavorini F, et al. Clinical and cost effectiveness of
switching asthma patients from ﬂuticasone-salmeterol to
extra-ﬁne particle beclometasone-formoterol: a retrospec-
tive matched observational study of real-world patients.
Prim Care Respir J 2013;22:439—48.
18] Lee IH, Bloor K, Hewitt C, Maynard A. International
experience in controlling pharmaceutical expenditure:
inﬂuencing patients and providers and regulating industry
— a systematic review. J Health Serv Res Policy 2015;1:
52—9.
19] Reechaipichitkul W, Thavornpitak Y, Sutra S. Burden of adult
pneumonia in Thailand: a nation wide hospital admission
data 2010. J Med Assoc Thai 2014;97:283—92.
20] Frei CR, Mortensen EM, Copeland LA, Attridge RT, Pugh MJ,
Restrepo MI, et al. Disparities of care for African-Americans
and Caucasians with community-acquired pneumonia: a ret-
rospective cohort study. BMC Health Serv Res 2010;10:143.
21] Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-
Aymerich J, Puhan MA. Antibiotics for exacerbations of
chronic obstructive pulmonary disease. Cochrane Database
Syst Rev 2012;12, http://dx.doi.org/10.1002/14651858.
CD010257.
22] Boucher BA, Kuhl DA, Coffey BC, Fabian TC. Drug use
in a trauma intensive-care unit. Am J Hosp Pharm
1990;47:805—10.
23] Spaulding EH. Studies on the chemical sterilization of sur-
gical instruments. Surg Gynecol Obstet 1939;69:738—44.
24] Carson LA, Favero MS, Bond WW, Petersen NJ. Mor-
phological, biochemical and growth characteristics of
Pseudomonas cepacia from distilled water. Appl Microbiol
1973;25:476—83.
25] Sapey E, Stockley RA. COPD exacerbations. 2: aetiology.
Thorax 2006;61:250—8.
26] Gupta D, Agarwal R, Aggarwal AN, Maturu VN, Dhooria S,
Prasad KT, et al. Guidelines for diagnosis and management
of chronic obstructive pulmonary disease: Joint ICS/NCCP
(I) recommendations. Lung India 2013;30:228—67.
27] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Camp-
bell GD, Dean NC, et al. Infectious Diseases Society of
America/American Thoracic Society consensus guidelines
on the management of community-acquired pneumonia in
adults. Clin Infect Dis 2007;44(Mar (Suppl 2)):S27—72.
28] Ober C, Yao TC. The genetics of asthma and allergic disease:
a 21st century perspective. Immunol Rev 2011;242:10—30.
29] Coco AS. Cost-effectiveness analysis of treatment options
for acute otitis media. Ann Fam Med 2007;5:29—38.
30] Khasawneh FA, Karim A, Mahmood T, Ahmed S, Jaffri
SF, Mehmood M. Safety and feasibility of antibiotic de-
escalation in bacteremic pneumonia. Infect Drug Resist
2014;7:177—82.
31] Reeder CE. Overview of pharmacoeconomics and pharma-
ceutical outcomes evaluations. Am J Health Syst Pharm
1995;52:5—8.
32] Sandler DA, Martin JF. Autopsy proven pulmonary embolism
in hospital patients: are we detecting enough deep vein
thrombosis. J R Soc Med 1989;82:203—5.
33] Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar W.
The changing pattern of venous thromboembolic disease.
Haemostasis 1996;26:65—71.
34] Sperry KL, Key CR, Anderson RE. Toward a population-based
assessment of death due to pulmonary embolism in New
Mexico. Hum Pathol 1990;21:159—65.
35] Shorr AF. The pharmacoeconomics of deep vein thrombosis
treatment. Am J Med 2007;120:35—41.
R  dise
[
[
[
[
[ational  drug  use  policies  in  the  respiratory  system
36] Moores LK, Jackson Jr WL, Shorr AF, Jackson JL. Meta-
analysis: outcomes in patients with suspected pulmonary
embolism managed with computed tomographic pulmonary
angiography. Ann Intern Med 2004;141:866—74.
37] Shorr AF, Ramage AS. Enoxaparin for thromboprophylaxis
after major trauma: potential cost implications. Crit Care
Med 2001;29:1659—65.38] Chan CM, Woods CJ, Shorr AF. Comparing the pulmonary
embolism severity index and the prognosis in pulmonary
embolism scores as risk stratiﬁcation tools. J Hosp Med
2012;7(January (1)):22—7.
[
Available  online  at  www
ScienceDases  51
39] Poole P, Black PN, Cates CJ. Mucolytic agents for chronic
bronchitis or chronic obstructive pulmonary disease.
Cochrane Database Syst Rev 2012;8, http://dx.doi.org/
10.1002/14651858.CD001287.
40] Katzung BG, Masters SB, Trevor AJ. Basic & clinical pharma-
cology book. In: Boushey HA, editor. Drugs used in asthma.
12th ed. McGraw Hill Lange; 2014. p. 375—88.
41] Tsiachristas A, Cramm JM, Nieboer AP, Rutten-van Mölken
MP. Changes in costs and effects after the implementation
of disease management programs in the Netherlands: vari-
ability and determinants. Cost Eff Resour Alloc 2014;12:17.
.sciencedirect.com
irect
